Ulisse Biomed Spa
MIL:UBM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.71
1.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IT |
|
Ulisse Biomed Spa
MIL:UBM
|
19.5m EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
| Min | -79 476% |
| 30th Percentile | 3.9% |
| Median | 8.7% |
| 70th Percentile | 14.4% |
| Max | 813.7% |
Other Profitability Ratios
Ulisse Biomed Spa
Glance View
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Ulisse Biomed Spa is -570.8%, which is above its 3-year median of -2 170.7%.
Over the last 3 years, Ulisse Biomed Spa’s Operating Margin has decreased from -537.5% to -570.8%. During this period, it reached a low of -7 245.5% on Dec 31, 2023 and a high of -537.5% on May 30, 2022.